
Study Period | 2022 - 2030 |
Market Size (2025) | USD 7.44 Billion |
Market Size (2030) | USD 19.33 Billion |
CAGR (2025 - 2030) | 21.03 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Low |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
SNP Genotyping Market Analysis
The SNP Genotyping Market size is estimated at USD 7.44 billion in 2025, and is expected to reach USD 19.33 billion by 2030, at a CAGR of 21.03% during the forecast period (2025-2030).
The SNP genotyping market is driven by the miniaturization of equipment and instruments, significant applications of SNP genotyping in chronic and genetic disorders detection, advantages of SNP genotyping and strategic initiatives by market players to introduce new products in the market.
Single nucleotide polymorphism (SNP) technologies are extensively utilized for detection and are beneficial in the etiology of several human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, among others. For instance, an article published in Nature Reviews Bioengineering Journal in March 2023 mentioned that a portable device utilizing a microarray system functionalized with fluorescently quenched toehold probes allows for multiplex single-nucleotide discrimination and enables the typing of single-nucleotide polymorphisms (SNPs). This battery-operated device can also be combined with a toroidal convection chamber for Polymerase chain reaction (PCR), facilitating device miniaturization and point-of-care use. Therefore, the rising applications of SNPs in several aspects of life sciences and biotechnology are driving the SNP genotyping market.
Additionally, the significant advantages of SNP genotyping are likely to promote its adoption, thus fuelling the market growth. For instance, an article published in the Journal of Biosensors (Basel) in September 2023 mentioned that electrochemical SNP biosensors offer several benefits, including affordability, rapid response times, high sensitivity, and ease of miniaturization. These biosensors can detect single-nucleotide polymorphisms (SNPs) associated with various diseases and improve early diagnosis. Thus, due to such advantages, these biosensors are likely to be adopted, contributing to market growth.
Furthermore, the launch of new biological products, acquisitions, collaborations, and regional expansions are some of the strategic initiatives adopted by the companies to maintain stability in the market. For instance, in January 2024, Thermo Fisher Scientific launched the Axiom PangenomiX Array, designed to enhance disease risk and detection research, facilitate population-level disease studies, support ancestry and wellness testing, evaluate drug efficacy, and contribute to drug development research. The PangenomiX Array is integrated with four assays into a single test, which includes SNP genotyping, whole-genome copy number variant detection, fixed copy number discovery, and blood and human leukocyte antigen (HLA) typing. This is likely to fuel market growth in the near future.
Therefore, owing to the above-mentioned factors, such as SNP genotyping applications in disease detection, significant advantages, and product launches, the studied market's growth over the forecast period is collectively responsible. However, the lack of standardization in SNP processes and privacy concerns posing a threat to broad technology applications are the major factors hindering market growth.
SNP Genotyping Market Trends
Pharmacogenomics Segment Expected to Witness High Growth Over the Forecast Period
Pharmacogenomics is a field of research that studies how a person's genes affect how someone responds to medications. The significant share of pharmacogenomics is primarily due to the increasing pipeline for personalized medicine and novel drug delivery systems, which extensively exploit SNP in genetic materials for drug development applications.
The government initiatives to fuel the enhancement of the pharmacogenomics field are anticipated to contribute to the segment growth. For instance, in September 2024, the Department of Health - Abu Dhabi (DoH) revealed that pharmacogenomic (PGx) reports can be accessed via the Malaffi platform, enabling tailored treatment plans for patients and improving the efficiency and quality of care in the Emirate. These PGx reports help reduce adverse drug reactions and increase treatment effectiveness by considering individual genomic profiles. Additionally, the genomic database established by the Emirati Genome Programme further protects the health and well-being of the community. Thus, such government initiatives to enhance the pharmacogenomics field are likely to propel the segment growth.
Further, the significance of SNP genotyping in translational research of drugs is expected to boost the segment growth. For instance, an article published in the Journal of Pharmacological Research in February 2024 mentioned that SNP-based pharmacogenomics targets for non-steroidal anti-inflammatory drugs (NSAIDs) usage emerge from the understanding that variations in response to these medications may be linked to either heightened drug exposure, potentially due to impaired drug metabolism or genetically influenced reduced cyclooxygenase (COX) enzymes activity. This combined effect could enhance both the therapeutic benefits and the adverse effects of NSAIDs.
Additionally, obtaining informed consent (IC) for pharmacogenomic testing is likely to enhance patient awareness, hence anticipated to drive the segment growth. For instance, a study published in the Journal of Pharmacology in February 2024 reported that 74% of respondents from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and National Society of Genetic Counselors (NSGC), among others, gathered informed consent from patients during February and March of 2023. The findings indicated that 67% of institutions discuss the benefits, explanation, and purpose of pharmacogenomic testing with patients. Thus, the implementation of the practice of informed consent for pharmacogenomic testing is expected to fuel the segment growth.
Hence, the growing demand for pharmacogenomics and government initiatives are expected to propel the SNP genotyping market in this segment.

North America Expected to Grow Significantly in the SNP Genotyping Market Over the Forecast Period
The United States is expected to witness significant growth within North America. Various factors, such as the rising burden of chronic diseases and increasing research investments in the region, are anticipated to fuel the market growth.
The region's continuously increasing burden of chronic diseases, including the United States, Canada, and Mexico, is expected to create demand for genotyping tools and services. For instance, the data released by the American Cancer Society in January 2024 estimated that around 2.0 million new cancer cases were expected to be diagnosed in the United States in 2024, which increased from 1.9 million cancer cases in 2023. Additionally, the data published by the Canadian Institute for Health Information in August 2023 mentioned that approximately 20% of Canadians face a mental illness annually. Genotyping techniques can be used for the early diagnosis and treatment of chronic diseases. The high burden of cancer and mental diseases is expected to boost the market growth.
Also, the healthcare industry in the region is deeply invested in applying innovative solutions, such as genotyping, to enhance the development of advanced disease diagnoses to help in patient care. For instance, in September 2024, the National Institutes of Health (NIH) allocated USD 5.4 million in initial funding to launch a new initiative to incorporate genomics into learning health systems. With the growing prevalence of genomic testing and the increasing availability of genomic data in clinical environments, learning health systems offer a valuable opportunity to rapidly and effectively transform this evidence into enhancements in medical treatment. Thus, the increasing funding by research institutes to support genomics is likely to boost the adoption of SNP genotyping, driving the market's growth.
Thus, the factors mentioned above, such as the increasing prevalence of chronic diseases and rising funding by research institutes, are expected to drive significant growth over the forecast period.

SNP Genotyping Industry Overview
The SNP genotyping market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold significant market shares and are well known, including Agilent Technologies Inc., Bio-Rad Laboratories Inc., LGC Group, Douglas Scientific LLC, Illumina Inc., and Luminex Corporation, among others.
SNP Genotyping Market Leaders
-
Thermo Fisher Scientific Inc.
-
Agilent Technologies
-
Bio-Rad Laboratories Inc.
-
Illumina Inc.
-
LGC Group
- *Disclaimer: Major Players sorted in no particular order

SNP Genotyping Market News
- August 2024: Amoneta Diagnostics SAS received Conformité Européene (CE) marking for its APO-Easy genotyping kit in accordance with the European Union (EU) In Vitro Diagnostic Regulation 2017/746 (IVDR). The APO-Easy Genotyping Kit is a ready-to-use qualitative in vitro diagnostic (IVD) test that utilizes real-time polymerase chain reaction (RT-PCR) for the accurate detection of two single-nucleotide polymorphisms (SNPs): rs429358 and rs7412 associated with Alzheimer's disease.
- April 2024: Applied BioCode Inc. unveiled its newest product, the BioCode STI + Resistance Panel for research use only (RUO). This multiplex nucleic acid amplification test is specifically designed to qualitatively identify DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG), along with macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations in a single assay.
SNP Genotyping Industry Segmentation
As per the scope of the report, single-nucleotide polymorphism (SNP) refers to mutations found at a specific locus or single base-pair mutation containing two alleles. SNPs aid in understanding the correlations between the genotype and behavior indicated by all living organisms. The SNP genotyping market is segmented by technology, usage and geography. By technology, the market is segmented into TaqMan SNP genotyping, massarray SNP genotyping, SNP GeneChip arrays, and other technologies. Other technologies include SNP Pyrosequencing, Real-time PCR-based SNP Genotyping and others. By usage, the market is segmented into pharmacogenomics and diagnostic field. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
By Technology | TaqMan SNP Genotyping | ||
Massarray SNP Genotyping | |||
SNP GeneChip Arrays | |||
Other Technologies | |||
By Usage | Pharmacogenomics | ||
Diagnostic Field | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle-East and Africa | GCC | ||
South Africa | |||
Rest of Middle-East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
SNP Genotyping Market Research FAQs
How big is the SNP Genotyping Market?
The SNP Genotyping Market size is expected to reach USD 7.44 billion in 2025 and grow at a CAGR of 21.03% to reach USD 19.33 billion by 2030.
What is the current SNP Genotyping Market size?
In 2025, the SNP Genotyping Market size is expected to reach USD 7.44 billion.
Who are the key players in SNP Genotyping Market?
Thermo Fisher Scientific Inc., Agilent Technologies, Bio-Rad Laboratories Inc., Illumina Inc. and LGC Group are the major companies operating in the SNP Genotyping Market.
Which is the fastest growing region in SNP Genotyping Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in SNP Genotyping Market?
In 2025, the North America accounts for the largest market share in SNP Genotyping Market.
What years does this SNP Genotyping Market cover, and what was the market size in 2024?
In 2024, the SNP Genotyping Market size was estimated at USD 5.88 billion. The report covers the SNP Genotyping Market historical market size for years: 2022, 2023 and 2024. The report also forecasts the SNP Genotyping Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
SNP Genotyping Industry Report
The SNP Genotyping and Analysis Market is segmented by technology and end-user, covering a wide range of techniques including TaqMan SNP Genotyping, Massarray SNP Genotyping, and SNP GeneChip Arrays. The market analysis provides a comprehensive industry overview, highlighting the significant growth rate and market trends within this sector. The industry report includes market research and statistics, offering valuable insights into the market size, market share, and market value.
The industry analysis reveals that North America, Europe, Asia-Pacific, Middle-East and Africa, and South America are key regions contributing to the market growth. The market forecast and industry outlook predict continued expansion, driven by advancements in pharmacogenomics and diagnostic fields. The report example and report PDF download offer detailed industry information, including market segmentation and market predictions.
The market review and market data emphasize the role of market leaders in shaping the industry trends and market outlook. The report also covers industry sales and market growth, providing a thorough market overview and industry research. The industry reports and market forecast offer a historical perspective and a forward-looking analysis, ensuring a well-rounded understanding of the SNP Genotyping and Analysis Market.
Overall, this report serves as an essential resource for research companies and stakeholders, offering critical industry statistics and market segmentation details. The report underscores the importance of industry size and market predictions in strategizing for future market opportunities.